PSORCON E
Clinical safety rating: caution
Comprehensive clinical and safety monograph for PSORCON E (PSORCON E).
Corticosteroid that binds to glucocorticoid receptors, modulating gene expression to produce anti-inflammatory, antipruritic, and vasoconstrictive effects.
| Metabolism | Primarily hepatic via CYP3A4; undergoes phase II conjugation. |
| Excretion | Primarily hepatic metabolism followed by renal excretion of metabolites; less than 5% excreted unchanged in urine. Biliary/fecal elimination accounts for <2%. |
| Half-life | Terminal elimination half-life is approximately 6-8 hours for the parent compound; active metabolites may have half-lives up to 12 hours. Clinically, this supports twice-daily dosing. |
| Protein binding | Approximately 85-90% bound to plasma proteins, primarily albumin and corticosteroid-binding globulin. |
| Volume of Distribution | Volume of distribution is approximately 1.2-1.5 L/kg, indicating extensive tissue distribution beyond plasma volume. |
| Bioavailability | Topical bioavailability is less than 1% through intact skin; systemic absorption increases with occlusive dressings, inflamed skin, or high potency formulations. Not available orally or parenterally. |
| Onset of Action | Topical application: Onset of anti-inflammatory effect within 1-2 hours; peak vasoconstriction observed at 4-6 hours. |
| Duration of Action | Duration of action is 12-24 hours for anti-inflammatory effect; clinical improvement may persist for several days after discontinuation. Twice-daily dosing is recommended for sustained effect. |
Topical: Apply a thin film to affected skin areas twice daily. No systemic dosing applicable.
| Dosage form | OINTMENT |
| Renal impairment | No dose adjustment required for renal impairment as systemic absorption is minimal. |
| Liver impairment | No dose adjustment required for hepatic impairment as systemic absorption is minimal. |
| Pediatric use | Apply a thin film to affected skin areas twice daily; use lowest effective potency for shortest duration due to increased risk of systemic absorption. |
| Geriatric use | Apply a thin film to affected skin areas twice daily; use caution due to thinner skin and increased potential for systemic effects; limit treatment duration. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for PSORCON E (PSORCON E).
| Breastfeeding | Diflorasone diacetate is minimally absorbed after topical application. Excretion in breast milk is unlikely to be clinically significant. Use caution when applying to large areas or for prolonged periods. No M/P ratio is available; use lowest effective dose on smallest area possible. |
| Teratogenic Risk | Topical corticosteroids like PSORCON E (diflorasone diacetate) are generally considered low risk for teratogenicity when used at recommended doses. However, prolonged or high-dose use during the first trimester may be associated with a small increased risk of orofacial clefts. During the second and third trimesters, high systemic exposure may cause fetal adrenal suppression and growth retardation. Avoid use over large body surface areas or occlusive dressings. |
■ FDA Black Box Warning
No FDA black box warning.
| Serious Effects |
["Hypersensitivity to diflorasone diacetate or other corticosteroids","Untreated bacterial, fungal, viral, or parasitic skin infections","Tuberculosis or syphilis of the skin","Rosacea, perioral dermatitis, acne vulgaris","Vaccination reactions"]
| Precautions | ["Reversible HPA axis suppression with prolonged use or large doses","Topical use may cause systemic effects including Cushing's syndrome, hyperglycemia, and glucosuria","Avoid occlusive dressings unless directed","Use caution in pediatric patients due to increased absorption","Local adverse reactions: skin atrophy, striae, telangiectasias, purpura, hypertrichosis, acneiform eruptions, hypopigmentation, allergic contact dermatitis"] |
Loading safety data…
| Fetal Monitoring | Monitor maternal adrenal function if prolonged or high-dose use is necessary. Fetal monitoring with ultrasound for growth parameters if repeated high-potency corticosteroid use occurs. |
| Fertility Effects | In animal studies, high systemic doses of corticosteroids may impair fertility. However, topical use at recommended doses is unlikely to affect human fertility. |